Generic Stomach Remedies Expand Their Waistline, 2001 PLMA Report Shows
This article was originally published in The Tan Sheet
Private label stomach remedy sales rose 5.4% to $79.8 mil. in mass merchandise outlets in 2000, an 18.4% dollar share for the year, according to PLMA's annual "Private Label Yearbook".
You may also be interested in...
Perrigo's private label famotidine 10 mg was approved by FDA May 31, ending a drawn out delay of the generic launch.
SmithKline Beecham expects to introduce Nicorette Orange in drug stores, mass market outlets and supermarkets nationwide near the end of October.
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC